GNFTF - Gilead's Mousetrap
My previous article forecast problems for selonsertib, as new research indicates that this drug targets mouse-specific pathways that are not present in humans. NASH cirrhosis trials continue to struggle. Intercept’s Ocaliva, a “NASH cirrhosis” drug candidate, is hailed as a Gilead’s acquisition target while fraught with serious adverse effects and long term safety considerations.
Introduction
In my previous article, Update On NASH Antifibrotics: Allergan, Gilead, Conatus, Galectin, I speculated that Gilead Sciences’ (GILD) selonsertib, an ASK-1 inhibitor for the treatment of NASH fibrosis and cirrhosis, may not work at all. Hepatocyte ballooning